Table 1.

Categories of in vitro BCR response of 70 CLL short-term cultures and their associations with clinical parameters and tumor features

Pattern of response to BCR stimulation	Correlation with
pERK1/2 activation at 2 h	High baseline pAKT (P = .06), short TTT (P = .05)
Code (n): 0 (12), 1 (2), 2 (5), 3 (3)	Lower in CLL with isolated -13q14 (P = .04)
pS473AKT activation at 2 h	TCL1 (P <.001), pan-pAKT target induction (P = .04), baseline pAKT (P = .05)
Strong: 36% (25 of 70)	sIgM and Rai stage (both P = .04), WBC and CD20 expression (both P = .02)
Mild: 41% (29 of 70)	Risk of not achieving a CR after F- and FCR-based frontline therapy (both P = .04)
None: 23% (16 of 70)	Inversely with maximum BCR-induced growth (P = .02)
TCL1 protein increase at 2 h	2-hour pAKT response (P = .003), high baseline pAKT (P = .01)
Yes (n = 13), no (n = 53)	More likely in +12 (P = .02) and less likely in -11q22-23 karyotypes (P = .03)
	Low peak WBC (P = .03), low no. of treatments (P = .02), long TTT (P < .001)
Growth induction at 48 h	Major determinant: 2-hour pAKT response (P < .001) and maximum BCR-induced growth amplitude (P < .001)
Hyperresponsive: 28% (8 of 29) Dose-dependent: 34% (10 of 29)	Hyperresponsive group: higher in vitro baseline growth (P = .002), lower IL-4/CD40L-induced growth (P = .03), higher sIgM (P = .07), and baseline pAKT and CD25 expression (both P = .08)
No response: 38% (11 of 29)	Dose-dependent growth: high CD38 (P = .03) and WBC, short LDT and TTT (all P = .06), high Rai stage (P = .07)